<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967612</url>
  </required_header>
  <id_info>
    <org_study_id>PJV2002</org_study_id>
    <nct_id>NCT04967612</nct_id>
  </id_info>
  <brief_title>Visual Perception After Virtual Implantation</brief_title>
  <official_title>Evaluation of Visual Perception Through Diffractive Optical Lens Designs by Virtual Implantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of visual perception through diffractive optical lens designs by virtual&#xD;
      implantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Actual">August 19, 2021</completion_date>
  <primary_completion_date type="Actual">August 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected distance visual acuity</measure>
    <time_frame>during the intervention</time_frame>
    <description>Evaluate visual acuity at distance following virtual implantation of diffractive optical lens designs</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Virtual implantation of diffractive optical lens design A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Virtual implantation of diffractive optical lens design B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Virtual implantation of diffractive optical lens design C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Virtual implantation</intervention_name>
    <description>Temporary placement of virtual optical lens in the crystalline lens plane.</description>
    <arm_group_label>Virtual implantation of diffractive optical lens design A</arm_group_label>
    <arm_group_label>Virtual implantation of diffractive optical lens design B</arm_group_label>
    <arm_group_label>Virtual implantation of diffractive optical lens design C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects between and including 18 and 50 years of age;&#xD;
&#xD;
          -  Healthy eyes;&#xD;
&#xD;
          -  Dominant eye with a monocular CDVA ≥1.0 decimal (≤ 0.0 logMAR) without cycloplegia;&#xD;
&#xD;
          -  Subject who has been informed of the consequences and constraints of the protocol and&#xD;
             who has given his/her written informed consent;&#xD;
&#xD;
          -  Negative COVID19 screening test prior to every trial visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects of less than 18 or more than 50 years of age;&#xD;
&#xD;
          -  Monocular CDVA of dominant eye &lt; 1.0 decimal (&gt; 0.0 logMAR) without cycloplegia;&#xD;
&#xD;
          -  Subject unable to comply with the study protocol or likely to be non-cooperative&#xD;
             during the study;&#xD;
&#xD;
          -  Subject whose freedom is impaired by administrative or legal issues, or adult persons&#xD;
             under legal protection or unable to give an informed consent;&#xD;
&#xD;
          -  Pseudophakic subjects;&#xD;
&#xD;
          -  Subjects, who are unable to fixate for a longer time, e.g. strabismus, nystagmus;&#xD;
&#xD;
          -  Pathologic miosis;&#xD;
&#xD;
          -  Intake of drugs affecting vision;&#xD;
&#xD;
          -  Participation in another biomedical study in parallel, if it affects vision or if&#xD;
             interactions with cycloplegia exist;&#xD;
&#xD;
          -  Intolerance to or contraindication to cycloplegia, e.g. due to narrow angle of the&#xD;
             anterior ocular chamber;&#xD;
&#xD;
          -  Hyperopes with more than +6 D refraction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W Sickenberger, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>JenVis Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JenVis Research</name>
      <address>
        <city>Jena</city>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

